{"id":342063,"date":"2023-04-05T00:00:00","date_gmt":"2023-04-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0109-biopharma-ovarian-cancer-epidemiology-epidemiology-dashboard\/"},"modified":"2026-05-29T23:20:03","modified_gmt":"2026-05-29T23:20:03","slug":"epidon0109-biopharma-ovarian-cancer-epidemiology-epidemiology-dashboard","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0109-biopharma-ovarian-cancer-epidemiology-epidemiology-dashboard\/","title":{"rendered":"Ovarian Cancer &#8211; Epidemiology &#8211; Epidemiology Dashboard"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of <abbr data-abbreviation-entity=\"4729\" title=\"non-small-cell lung cancer\">ovarian cancer<\/abbr> comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.<\/p>\n<p>Ovarian cancer forecast data are available on Clarivate\u2019s Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr> forecast answers the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr> and the number of new diagnoses of <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr>, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"age-related macular degeneration\">ovarian cancer<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed ovarian cancer all sites incident cases<\/li>\n<li>Diagnosed epithelial ovarian cancer incident cases<\/li>\n<li>Diagnosed fallopian tube cancer incident cases<\/li>\n<li>Diagnosed primary peritoneal cancer incident cases<\/li>\n<li>BRCA mutation<\/li>\n<li>Stage at diagnosis ovarian cancer all sites<\/li>\n<li>Stage at diagnosis epithelial ovarian cancer<\/li>\n<li>Stage of diagnosis fallopian tube cancer<\/li>\n<li>Stage at diagnosis primary peritoneal cancer<\/li>\n<li>Prevalence ovarian cancer all sites<\/li>\n<li>Prevalence epithelial ovarian cancer<\/li>\n<li>Prevalence fallopian tube cancer<\/li>\n<li>Prevalence primary peritoneal cancer<\/li>\n<li>Recurrence<\/li>\n<li>Ovarian cancer drug treatable populations<\/li>\n<li>Ovarian cancer drug treated and non-drug treated populations<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country<\/p>\n","protected":false},"template":"","class_list":["post-342063","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/342063","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/342063\/revisions"}],"predecessor-version":[{"id":342301,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/342063\/revisions\/342301"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=342063"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}